INTRODUCTION
Heparan sulfate proteoglycans (HSPG) are thought to serve as extracellular binding partners for secreted signaling molecules. They participate in establishing and maintaining morphogen gradients that play central roles in establishing position and identity of cells to create the architecture of developing tissues [1] [2] [3] [4] . Gradients are also recognized determinants of events in adult organisms though these have largely been explored based on the level of particular cytokines 5, 6 . Electrostatic interactions of cytokines with heparan sulfate proteoglycans (HSPG) restrict diffusion and permit gradients to persist, perhaps revealing why HSPG are uniformly present in all metazoa [7] [8] [9] .
In hematopoiesis, HSPG have been implicated in a variety of processes. In vitro studies performed in the 1980s and 1990s described the interaction of HSPGs with key hematopoietic cytokines and theorized a potential role in bone marrow compartmentalization [10] [11] [12] . These studies provided the first evidence that the effect exerted by cytokines such as GM-CSF and IL-3 depended on the integrity of the HSPGs to which they are bound: enzymatic or chemical degradation of HSPGs impaired the effects of the cytokines in vitro. More recently, in vivo administration of naturally occurring and synthetic HSPG mimetics has been shown to induce rapid mobilization of hematopoietic stem and progenitor cells [13] [14] [15] from the BM to the peripheral blood, likely by modulating CXCL12 levels 14 . In contrast, overexpression of the HSPG-cleaving enzyme heparanase, in mice, results in an accumulation of HSPCs in the BM due to an increase of CXCL12 turnover and reduced activity of proteolytic enzymes in the BM 16 . Moreover, Khurana and colleagues recently demonstrated that glypican-3, a HSPG family member, inhibits the extracellular dipeptidylpeptidase, CD26 17 , implicated in HSPC homing and mobilization 18, 19 .
Our laboratory recently described a population of bone marrow (BM) skeletal stem/progenitors characterized by the interferon inducible expression of the Myxovirus resistance 1 (Mx1) gene 20 . These cells participate in bone homeostasis and partially overlap with the Nestin1+ stromal population shown to be a component of the HSPC niche 21 . We hypothesized that cytokines and morphogens maintained by interaction with locally secreted matrix proteins are essential in maintaining the hematopoietic stem/progenitor cell (HSPC) niche. To test this, we conditionally deleted the Ext1 gene, a glycosyltransferase essential for the synthesis of heparan sulfate (HS) 9, 22 , in Mx1+ stromal cells. Our data demonstrate that Ext1/HSPG expressed in Mx1+ stromal cells and their descendants control HSPC localization and retention in the BM, in part by modulating vascular cell
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From 4 adhesion molecule-1, Vcam1. Competitive pharmacologic inhibition of endogenous HS enhanced the mobilization efficacy of Granulocyte-Colony Stimulating Factor (G-CSF) including in the setting of mobilization resistance in a diabetes model. Further, the mobilized HSPCs had improved kinetics of reconstitution in primary and secondary transplants in irradiated hosts. Finally, engraftment of transplanted HSPCs occurred efficiently without cytotoxic conditioning shortly after mice were rendered Ext-1 deficient. These findings demonstrate the critical role of HS in the bone marrow hematopoietic stem cell niche and suggest that targeting HS or the enzyme, Ext1, may provide novel methods for achieving outcomes in either mobilization or engraftment that are of importance for clinical HSPC transplantation.
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MATERIAL AND METHODS

Mice
EXT1
flox/flox mice were previously described (Inatani et al., 2003) . C57BL/6J, B6.SJL-Ptprca Pep3b/BoyJ (B6.SJL), Mx1-Cre (B6.Cg-Tg(Mx1-cre)1Cgn/J), Rosa26-loxP-stop-loxP-EYFP (Rosa-YFP, B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J) and Col2.3-GFP (B6.Cg-Tg(Col1a1*2.3-GFP)1Rowe/J) mice were purchased from Jackson laboratory. Six to twelve week old male mice were used. Polyinosinic-polycytidylic acid (pIpC) was obtained from Amersham (GE-Healthcare Life Sciences) and administered by intraperitoneal (i.p.) injection at a dose of 25mg/kg of total body weight (TBW) in PBS every other day for four days. Harvard University Institutional Animal Care and Use Committee (IACUC) and the Subcommittee on Research Animal
Care of the Massachusetts General Hospital approved all animal work.
Flow cytometry analysis
Immunophenotypic characterization of the hematopoietic and stromal compartments was performed as previously described 23 . For details see supplementary information. Vcam1 and Cxcl12 protein levels were evaluated with an anti-Vcam1-APC and an anti-Cxcl12-APC antibody respectively and the corresponding isotype controls (R&D Systems). All data collection was performed on an LSRII or FACS Aria II (Beckon Dickinson) and data analysis was performed with FlowJo (Treestar).
Transplantation assays
For non-competitive BM transplantation, to create the chimeras described in Fig.1c , one million whole BM cells from B6.SJL (CD45.1) mice were transplanted into lethally irradiated (9.5 Gy from a Cesium source 4-24 hours before transplantation) Ext1-loxP/loxP-Mx1cre (CD45.2) recipients six-to-eight weeks before pIpC administration. Neutrophil and platelet recovery assay was performed as previously described 24 . 
Intravital microscopy
In vivo imaging of HSPCs in the calvaria BM cavity and data analysis was performed as previously described
25
.
Briefly, FACS-sorted HSCs were stained in PBS for 15 min at 37°C with DiD (Invitrogen) using a 1:200 dilution and injected into lethally irradiated Ext1 control and mutant Col2.3-GFP+ recipients. Mice were imaged 24 hours later. Distance between HSCs, GFP+ osteoblastic cells and bone were measured using Image J software.
HSC mobilization and blood collection
Recombinant human G-CSF (Neupogen, Filgrastrim) was administered at 125 μ g/kg of TBW every 12 hours for eight consecutive injections. Heparin Sodium (APP Pharmaceuticals) was injected i.p. at a single dose of 100U. Hirudin was used at 40 mg/kg of TBW in a single dose. Vcam1 neutralizing antibody and the corresponding isotype control (Rat IgG2a, κ ) were injected intravenously at 2mg/kg of TBW every day for three doses and PB samples were obtained through retro-orbital bleeding the day following the last injection.
AMD3100 was administered subcutaneously at a single dose of 5mg/kg TBW. PB samples were obtained through retro-orbital bleeding 3 hours after the last injection of G-CSF and 1 hour after Heparin, AMD3100, or Hirudin injection.
Diabetic mouse model
Diabetes was induced in 4 to 6 week-old C57BL/6J or Ext1-loxP/loxP-Mx1cre male mice as previously described 26 . Only animals with glucose values higher than 300 mg/dl were used for experiments.
Statistical analysis
Unpaired, two-tailed Student's t test or one-way ANOVA followed by the appropriate post-hoc test were used.
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Data have been plotted as average ± SD for samples following a normal (Gaussian) distribution. Alternatively, Mann-Whitney U test was used and data have been plotted as median ± IQR (interquartile range). Statistical significance is indicated as follows: *P < 0.05; **P < 0.01; ***P < 0.001. 1a ). Mutant and control YFP+, CD45-, Ter119-skeletal progenitors were flow sorted twenty-one days after pIpC induction and efficient deletion of Ext1 was verified in ex vivo-expanded cells by western blotting (Fig.S1a-b) .
Furthermore, significant abrogation of HS production upon Ext1 deletion was detected in ex vivo expanded as well as freshly isolated Mx1+ stromal cells (Fig.S1c-d) . HS has been previously implicated in the maintenance of mesenchymal stem cells 28 . Importantly, deletion of Ext1 in our model did not affect the abundance of immunophenotypically defined mesenchymal/stromal stem cells in the BM (Fig.1b) . To restrict Ext1 deletion to Mx1+ skeletal progenitors, we transplanted total BM cells from CD45.1 expressing congenic animals (B6.SJL) into lethally irradiated mutant (Ext1flox/flox;Mx1cre+) or control (Ext1flox/flox;Mx1cre-) mice (both in C57BL/6J background) (Fig.1c) to create control and mutant chimeras. Six to eight weeks after transplantation the hematopoietic system was replaced by >95% CD45.1 cells (Fig.S1e ) and chimeric animals displayed equivalent hematopoietic parameters such as white blood cell (WBC), red blood cells (RBCs), platelet counts and WBC lineage distribution in the peripheral blood (PB) (Fig.S1f-i) . Ext1 was then deleted in nonhematopoietic cells by pIpC induction and hematopoiesis was monitored for 24 weeks. At 24-weeks post-pIpC, both control and mutant chimeric mice displayed comparable total body weight (TBW) and BM cellularity (Fig.S1j-k) . Bone marrow immunophenotypic analysis revealed a significant decrease in the proportion of Mac1+Gr1+ and CD3+ cells in mutant chimeras without a change in the B220+ population (Fig.1d) (Fig.1f) . These changes, however, could not be attributed to an increase in HSC death nor to a proliferation defect (Fig.1g-h ).
Given the lack of changes in apoptosis and cell cycle of HSCs in mutant chimeric mice, we assessed for mislocalization of HSPCs by examining the PB and spleen. During the 24-week time course, mutant chimeras developed a marked leukocytosis (Fig.2a) (with a significant increase in the numbers of lymphoid and myeloid cells in PB (Fig.2b) ) and a moderate thrombocytopenia with normal red blood cell (RBC) counts (Fig.S1l-m) .
In addition, PB colony forming assays (CFU-C) displayed a significant increase in circulating progenitors in mutant chimeric mice (Fig.2c) . Mutant chimeras had significantly larger spleens at 24 weeks post pIpC injection (Fig.2d) . Immunophenotypic characterization of the spleen revealed a substantial increase in the proportion of HSCs (Fig.2e) , CMPs and GMPs but not MEPs in these mice (Fig.2f) . The accumulation of HSCs in the spleen cannot be attributed to a resistance to cell death or to an increase in their proliferation (Fig.2g-h) . Furthermore, competitive transplantation of spleen cells from mutant chimeric mice with equal numbers of spleen cells from C57BL/6J mice revealed a significant, long term, competitive advantage compared to spleen cells from control chimeras (Fig.2i) . Contribution to blood cell lineages by HSCs from control and mutant chimeras in this transplantation experiment was equivalent (Fig.2j) . Mislocalization of HSPCs has been associated with neutrophil turnover and neutrophil-induced BM microenvironment changes 29 .
Distribution of circulating "aged" neutrophils ( Fig.S1n ) and BM Cxcl12 levels (Fig.S1o) were equivalent in control and mutant chimeric Ext1 mice suggesting that the neutrophilia observed in our model does not account for the HSPC mislocalization. Given that osteolineage cells have been shown to impact hematopoiesis in a number of murine models 30 we evaluated whether the observed HSPC mislocalization in Ext1 mutant mice was a consequence of impaired osteolineage cell function. Bone histomorphometric, micro CT and histologic analysis showed no significant differences, suggesting that Ext1 deletion in Mx1+ skeletal progenitors is not essential for skeletal homeostasis (Fig.2k, Fig.S1p , Table S1 and S2) at least over the intervals examined here. Taken together these results indicate that production of HS by a population of Mx1+ skeletal progenitors regulates HSPC retention in the BM cavity.
Heparan Sulfate modulates HSCs micro-anatomical positioning
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From Micro-anatomic positioning of HSPCs in the BM influences their heterotypic interactions altering activity and response to stimuli. We evaluated whether HSPC positioning in the BM was affected upon Ext1 deletion in Mx1+ skeletal progenitor cells. Control and mutant mice were bred into a reporter strain expressing GFP under the Col2.3 promoter (Col2.3-GFP), specifically labeling mature osteoblastic cells (Fig.3a) . Ext1 control and mutant Col2.3-GFP+ mice were lethally irradiated and transplanted with 10 4 WT LKS CD48-,CD150+ DiD (1,1′-dioctadecil-3,3,3′-tetramethylindodicarbocyanine perchlorate) labeled HSCs. Labeled HSCs were visualized in the calvarial BM 24 hours after injection by means of intra-vital high-resolution two-photon and confocal microscopy and their relative distance to osteoblastic cells (Col2.3-GFP+) and the endosteal surface was quantified. The anatomic positioning of DiD+ cells in the mutant animals was markedly changed with cells at a greater distance from GFP+ osteolineage cells (Fig.3b-c) .
Heparan Sulfate modulates Vcam1-dependent adhesion
To investigate whether HS affected the regulation of molecules known to modulate HSPC localization, control and mutant YFP+ (Fig.1a) , CD45-, Ter119-skeletal progenitors were flow sorted twenty-one days after pIpC induction. Assessment of mRNA levels revealed that the expression of Cxcl12, Vcam1, Scf and angiopoietin-1 30 , were significantly down regulated in mutant mice (Fig.4a) (Fig.4c-d) . To determine whether the observed reduction in Vcam1 expression functionally contributed to the mislocalization of HSPCs seen in Ext1-mutant chimeric mice we evaluated how the addition of a Vcam1 neutralizing antibody influenced G-CSF-induced HSPC mobilization in control and mutant animals ( neutralization without G-CSF administration (Fig.4h) . In summary, deletion of Ext1 and its HSPG products in Mx1+ skeletal progenitors reduces production of Vcam1 and other adhesion mediators rendering the region less functional as a site of stem cell retention.
Pharmacological competitive inhibition of heparan sulfate proteoglycans in vivo induces HSPC mobilization
HS mimetics have been shown to induce rapid HSPC mobilization in mice, putatively through competitive inhibition of endogenous HSPGs 13-15 . Heparin, a highly sulfated glycosaminoglycan, has been shown to lack the ability to induce mobilization on its own 13 . Surprisingly, we observed that heparin administration (100U/mouse one hour before PB harvest) induces a modest, yet significant increase in the number of circulating HSPCs as measured by CFU assays without a significant change in WBC counts ( Fig.S3a-b ).
Given our observations that the genetic deletion of HS production alters HSPC localization and that heparin is an inexpensive, FDA-approved drug, which competitively inhibits HSPG signaling, we investigated whether it could cooperate with the current G-CSF mobilization regimen (Fig.5a ). Mice treated with heparin (100U/mouse one hour before PB harvest) in combination with G-CSF displayed a modest (p>0.05) increase in the WBC count in PB compared to mice treated with G-CSF alone (Fig.5b) . However, the combination of heparin and G-CSF significantly increased the mobilization of long term reconstituting cells as measured by PB competitive transplantation into lethally irradiated congenic mice ( Fig.5c left panel) . Furthermore, these cells efficiently self-renewed as shown by their ability to engraft secondary recipients ( Fig.5c right panel) . Importantly, administration of heparin and G-CSF mobilized a population of HSCs with a distinct transcriptional signature compared to G-CSF alone (Fig.5d-f and Table S3 ), suggesting that HS competitive inhibition either mobilizes an additional population of HSPCs or the mobilization process is sufficiently different to rapidly alter gene expression characteristics.
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From Recovery of neutrophil and platelet counts defines successful engraftment after BM transplantation in clinical settings and time to recovery predicts survival 38 . Importantly, non-competitive transplantation of PB mobilized by means of co-administration of G-CSF and heparin resulted in four to six day quicker recovery of neutrophils ( Fig.5g ) and platelets ( Fig.5h ) compared with G-CSF alone. The combination of heparin and G-CSF did not increase HSPC mobilization over G-CSF alone in the Ext1 mutant mice, suggesting that heparin enhances G-CSF-induced mobilization in wild type mice by modulating endogenous HSPGs (Fig.5i) . Also, hirudin, a nonheparin based anticoagulant, did not impact G-CSF-induced HSPC mobilization (Fig.5j) indicating that the observed effect was not a consequence of heparin anticoagulation properties. Hematopoietic stem cell transplantation remains the gold standard curative therapy for a number of hematological disorders. However, G-CSF mobilization resistance may compromise HSPC transplant for some individuals. We therefore evaluated whether genetic or pharmacological competitive inhibition of HSPG may facilitate G-CSF-induced HSPC egress from the BM in a murine model of Type I diabetes-induced mobilopathy 26 . G-CSF failed to efficiently mobilize HSPCs in Type I diabetic mice. However, the compromised response to G-CSF was fully corrected in Type I diabetic mice lacking Ext1 expression in Mx1+ stromal cells (Fig.5k) . Furthermore, combination of heparin with G-CSF resulted in normal mobilization of long term reconstituting cells in diabetic animals as measured by PB competitive transplantation into lethally irradiated congenic mice (Fig.5l ). These data demonstrate that functional competitive inhibition of endogenous HSPGs rescues the mobilization abnormalities noted in animals with pharmacologically induced diabetes.
Pharmacological competitive inhibition of heparan sulfate modulates Vcam1-dependent adhesion
Next, we evaluated whether heparin induced mobilization was abrogated upon Vcam1 inhibition in the absence of G-CSF stimulation since Vcam1 is, at least partially, responsible for the defect observed in the Ext1 mutant mice. Administration of heparin enhanced HSPC mobilization compared to vehicle as measured by CFU assays (Fig.6a-b) . Conversely, co-administration of heparin and Vcam1 neutralizing antibodies failed to improve HSPC mobilization over Vcam1 neutralization alone, suggesting that heparin induces mobilization by modulating Vcam1-dependent adhesion ( Fig.6a-b) . However, administration of heparin one hour before PB harvest does not modulate Vcam1 levels in Mx1+ stromal cells (Fig.S3c) , suggesting that alternative mechanisms are implicated in the effect of heparin on Vcam1-dependent adhesion such as allosteric
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From interactions affecting the Vcam1-Vla4 interaction as previously shown 39 . Importantly, our results also show that co-administration of heparin enhances AMD3100-induced mobilization (Fig.6a , middle shadowed panels and Fig.6b) . Moreover, AMD3100, a Cxcr4 antagonist 40 , also augments G-CSF-induced mobilization in Ext1 deficient mice (Fig.6c) , suggesting that the role of HS in HSPC retention is independent of the Cxcl12-Cxcr4 axis.
Mx1+ stromal cells control engraftment of transplanted hematopoietic stem and progenitor cells
HSPC engraftment in the BM relies on the efficient evacuation of BM niches, often achieved by means of total body irradiation and high dose chemotherapy 41 . These conditioning methods are toxic and undesirable for patients who do not suffer from a malignancy requiring irradiation or high dose chemotherapy as part of the treatment plan. We evaluated whether abrogation of Ext1 in Mx1+ stromal cells may enable engraftment without cytotoxic conditioning. Three weeks after pIpC induction, control and mutant mice were transplanted with congenic CD45.1 BM cells and followed for 16 weeks. Notably, while control animals failed to engraft independently of the cell dose transplanted, mutant mice showed a significant increase in engraftment in a dose-dependent manner throughout the course of the transplant (Fig.7a) . Secondary transplantation to further define the enhanced HSC engraftment is the subject of future work. The engrafting cells demonstrated longterm multi-lineage reconstitution (Fig.7b) . Hence, Mx1+ stromal cell production of HSPGs modulates the process of HSPC engraftment in the BM suggesting that targeting HS may provide a means of enabling engraftment without cytotoxic pre-conditioning. Here, we present evidence that skeletal stem/progenitor cell production of HS control HSPC bone marrow retention, can be inhibited to mobilize more potent HSPC even in settings of mobilization resistance and may be targeted to enable non-toxic conditioning for HSPC engraftment. Through these data we show that Mx1-expressing stromal cells and/or their descendants comprise a population of cells that participate in a niche for hematopoietic stem cells (Fig.7c) . We regard these cells as most likely the bone marrow localized mesenchymal cells we previously defined 20 . However, it cannot be excluded that other populations of Mx1-expressing cells such as those in the liver or endothelial cells outside the bone marrow also contribute to the phenotype observed here. We note that this is a consideration for most if not all studies using gene modification in stromal elements since the promoters used for the recombinase are not constrained to a single cell type in vivo. The possible role of non-stromal, non-bone marrow cells may be particularly relevant for the leukocytosis observed here since adhesion characteristics such as VCAM-1 on micro-vessels could have been affected. We do not consider homing to be the basis for the HSPC changes however given the imaging studies and homing analyses presented above. Rather, we think these are most likely due to altered retention.
The data presented indicate that manipulation of endogenous HSPGs produced by Mx1-expressing cells can alter localization sufficiently to be of relevance to clinically important issues. First, co-administration of G-CSF and heparin mobilized qualitatively distinct HSPC with more rapid hematopoietic reconstitution and increased secondary transplant ability. These data suggest that combined use of these agents may favor the collection of highly potent HSPCs for transplantation. Further definition of the distinct subsets mobilized is the subject of future work, but the gene expression analysis presented may provide testable methods of discriminating the populations differentially mobilized when heparin was involved. Second, heparin or Ext1
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From deletion enhanced G-CSF induced HSPC mobilization even in the setting of G-CSF resistance induced by a diabetic phenotype. This suggests a potential clinical setting in which a combination approach may be both testable and, if validated, of clinical utility. Parenthetically, the pathophysiologic basis for the diabetic mobilization phenotype includes neuropathy 26 . Since the deletion of Ext1 prevents the development of the mobilization defect, it is intriguing to consider whether the biochemical activities of the enzyme play a role in the processes compromising neurologic function in diabetes. Our data do not address this experimentally, but
Ext1 has been shown to be of significance in neurologic development and may be worth evaluating in this setting of neural dysfunction 43 .
Finally, Ext1 deletion provided a context in which infused HSPC could engraft and achieve levels of chimerism meaningful for some non-malignant clinical conditions. It should be noted that the level of chimerism was more than double that seen when AMD3100 was used as a conditioning regimen by others using 5-fold more bone For Grey shadowed area is intended to highlight the fact that co-administration of heparin enhances AMD3100-induced mobilization.
(C) Relative PB reconstitution, 16 weeks post transplantation, of recipient CD45.1 mice transfused with PB from Ext1 control or mutant mice (CD45.2) receiving G-CSF alone or in combination with AMD3100. Recipient mice were lethally irradiated and received CD45.1 cells for radio-protection.
Data representative of at least 2 independent experiments, n=5-8 mice per genotype per experiment. In mobilization experiments, PB was collected from at least 5 mice per experimental group. Data are represented as mean ± SD or median ± IQR (interquartile range). * p<0.05; ** p<0.01; *** p<0.001. 
